As early results have indicated that 90Y-IT consolidation has a favorable tolerability profile, with low infection rates and a manageable hematologic toxicity, we carried out this study with CHOP plus rituximab followed by 90Y-IT in untreated elderly DLBCL patients, also reducing the number of CHOP cycles from six to four. The gene discussed is DDIT3; the disease is infection.